or Try an Advanced Search...

    ETF Components for OZEM - Roundhill GLP-1 & Weight Loss ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    NVO F -2.51 17.04
    LLY F -0.46 14.13
    ALT C 4.41 4.44
    AZN F 1.68 3.99
    VKTX F 0.19 3.39
    AMGN F 0.71 3.26
    PFE F 0.76 3.07
    SRRK C -4.27 2.80
    REGN F 0.15 2.40
    RYTM C -0.56 2.30
    TAK D 0.30 2.17
    TERN F 1.96 1.97
    CORT B -0.30 1.77
    OPK C -1.27 1.72

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Obesity Pharmaceutical Products Cancer Inflammation Biotechnology Diabetes Medicine Neuroscience S&P 500 Alzheimer's Disease Anemia Asthma Cholesterol Depressive Disorder Hormones Hypertension Life Sciences Major Depressive Disorder Medication
    Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic

    Recent News for Roundhill GLP-1 & Weight Loss ETF & its Holdings

    Date Stock Title
    Nov 21 PFE Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
    Nov 21 NVO The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
    Nov 21 VKTX Do Redditors Think That Viking Therapeutics Inc. (VKTX) Has a Big Upside Potential?
    Nov 21 LLY Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
    Nov 21 LLY Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed
    Nov 21 PFE Optimism over global healthcare sector rises: Jefferies
    Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 NVO Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 AMGN Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 CORT 3 Reasons Growth Investors Will Love Corcept (CORT)
    Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
    Nov 21 PFE Major companies that are also popular short-selling stocks
    Nov 21 LLY Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
    Nov 21 PFE 5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return
    Nov 21 AZN Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
    Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
    Nov 21 NVO Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
    Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
    Nov 21 TAK Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
    Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
    OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
    Weight Management Peptide Therapeutics
    Back to the Main OZEM Page...